In Phase C, individuals will get ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment until condition progression or even the individuals are unable to tolerate the study drugs. and after that advertise H3K27Ac at this region. Chromatin hyperacetylation could increase the https://beauujxjw.boyblogguide.com/31261405/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets